-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明，無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Cogent Biosciences (NASDAQ:COGT) & Abliva AB (Publ) (OTCMKTS:NEVPF) Financial Review
Cogent Biosciences (NASDAQ:COGT) & Abliva AB (Publ) (OTCMKTS:NEVPF) Financial Review
Abliva AB (publ) (OTCMKTS:NEVPF – Get Rating) and Cogent Biosciences (NASDAQ:COGT – Get Rating) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, risk, profitability and valuation.
Analyst Ratings
This is a breakdown of recent ratings and price targets for Abliva AB (publ) and Cogent Biosciences, as reported by MarketBeat.com.
Get Abliva AB (publ) alerts:| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Abliva AB (publ) | 0 | 0 | 0 | 0 | N/A |
| Cogent Biosciences | 0 | 0 | 3 | 0 | 3.00 |
Cogent Biosciences has a consensus target price of $21.33, indicating a potential upside of 46.02%. Given Cogent Biosciences' higher probable upside, analysts plainly believe Cogent Biosciences is more favorable than Abliva AB (publ).
Profitability
This table compares Abliva AB (publ) and Cogent Biosciences' net margins, return on equity and return on assets.| Net Margins | Return on Equity | Return on Assets | |
| Abliva AB (publ) | N/A | -159.15% | -120.99% |
| Cogent Biosciences | N/A | -73.27% | -42.95% |
Valuation and Earnings
This table compares Abliva AB (publ) and Cogent Biosciences' revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Abliva AB (publ) | $20,000.00 | 674.18 | -$14.40 million | ($0.04) | -1.25 |
| Cogent Biosciences | $7.87 million | 85.06 | -$72.27 million | ($2.48) | -5.89 |
Abliva AB (publ) has higher earnings, but lower revenue than Cogent Biosciences. Cogent Biosciences is trading at a lower price-to-earnings ratio than Abliva AB (publ), indicating that it is currently the more affordable of the two stocks.
Summary
Cogent Biosciences beats Abliva AB (publ) on 5 of the 9 factors compared between the two stocks.
About Abliva AB (publ)
(Get Rating)
Abliva AB (publ) develops medicines for the treatment of primary mitochondrial diseases. The company is developing KL1333 that is in Phase 2/3 clinical trials for the chronic treatment of primary mitochondrial diseases; NV354, which is in the preparation for clinical trials for the treatment of primary mitochondrial diseases with Complex I deficiency; and NeuroSTAT that is in Phase 1b/2a clinical study for traumatic brain injury. It has collaboration agreements with Isomerase, Yungjin Pharm, University of Pennsylvania, Children's Hospital of Philadelphia, and Oroboros Instruments. The company was formerly known as NeuroVive Pharmaceutical AB (publ) and changed its name to Abliva AB (publ) in May 2020. Abliva AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden.
About Cogent Biosciences
(Get Rating)
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Receive News & Ratings for Abliva AB (publ) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abliva AB (publ) and related companies with MarketBeat.com's FREE daily email newsletter.
Abliva AB (publ) (OTCMKTS:NEVPF – Get Rating) and Cogent Biosciences (NASDAQ:COGT – Get Rating) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, risk, profitability and valuation.
Abliva AB(Publ)(OTCMKTS：NEVPF-GET Rating)和Cogent Biosciences(納斯達克：COGT-GET Rating)都是小盤醫療公司，但哪隻股票更優越？我們將根據分析師推薦的收益、股息、機構所有權、風險、盈利能力和估值對這兩家公司進行對比。
Analyst Ratings
分析師評級
This is a breakdown of recent ratings and price targets for Abliva AB (publ) and Cogent Biosciences, as reported by MarketBeat.com.
據MarketBeat.com報道，這是Abliva AB(Publ)和Cogent Biosciences最近的評級和目標價細分。
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Abliva AB (publ) | 0 | 0 | 0 | 0 | N/A |
| Cogent Biosciences | 0 | 0 | 3 | 0 | 3.00 |
| 銷售評級 | 保持評級 | 購買評級 | 強勁的買入評級 | 評級分數 | |
| Abliva AB(酒吧) | 0 | 0 | 0 | 0 | 不適用 |
| 令人信服的生物科學 | 0 | 0 | 3 | 0 | 3.00 |
Cogent Biosciences has a consensus target price of $21.33, indicating a potential upside of 46.02%. Given Cogent Biosciences' higher probable upside, analysts plainly believe Cogent Biosciences is more favorable than Abliva AB (publ).
Coent Biosciences的共識目標價為21.33美元，表明潛在漲幅為46.02%。鑑於Cogent Biosciences更有可能上行，分析師們顯然認為Cogent Biosciences比Abliva AB(Publ)更有利。
Profitability
盈利能力
| Net Margins | Return on Equity | Return on Assets | |
| Abliva AB (publ) | N/A | -159.15% | -120.99% |
| Cogent Biosciences | N/A | -73.27% | -42.95% |
| 淨利潤率 | 股本回報率 | 資產回報率 | |
| Abliva AB(酒吧) | 不適用 | -159.15% | -120.99% |
| 令人信服的生物科學 | 不適用 | -73.27% | -42.95% |
Valuation and Earnings
估值和收益
This table compares Abliva AB (publ) and Cogent Biosciences' revenue, earnings per share (EPS) and valuation.
此表比較了Abliva AB(Publ)和Cogent Biosciences的收入、每股收益(EPS)和估值。
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Abliva AB (publ) | $20,000.00 | 674.18 | -$14.40 million | ($0.04) | -1.25 |
| Cogent Biosciences | $7.87 million | 85.06 | -$72.27 million | ($2.48) | -5.89 |
| 總收入 | 價格/銷售額比 | 淨收入 | 每股收益 | 市盈率 | |
| Abliva AB(酒吧) | $20,000.00 | 674.18 | -1,440萬美元 | ($0.04) | -1.25 |
| 令人信服的生物科學 | 787萬美元 | 85.06 | -7,227萬元 | ($2.48) | -5.89 |
Abliva AB (publ) has higher earnings, but lower revenue than Cogent Biosciences. Cogent Biosciences is trading at a lower price-to-earnings ratio than Abliva AB (publ), indicating that it is currently the more affordable of the two stocks.
Abliva AB(Publ)的收益比Cogent Biosciences高，但收入低。Coent Biosciences的市盈率低於Abliva AB(Publ)，這表明它目前是兩隻股票中更負擔得起的一隻。
Summary
摘要
Cogent Biosciences beats Abliva AB (publ) on 5 of the 9 factors compared between the two stocks.
在兩隻股票之間的9個因素中，有5個因素的表現優於Abliva AB(Publ)。
About Abliva AB (publ)
關於Abliva AB(Publ)
(Get Rating)
(獲取評級)
Abliva AB (publ) develops medicines for the treatment of primary mitochondrial diseases. The company is developing KL1333 that is in Phase 2/3 clinical trials for the chronic treatment of primary mitochondrial diseases; NV354, which is in the preparation for clinical trials for the treatment of primary mitochondrial diseases with Complex I deficiency; and NeuroSTAT that is in Phase 1b/2a clinical study for traumatic brain injury. It has collaboration agreements with Isomerase, Yungjin Pharm, University of Pennsylvania, Children's Hospital of Philadelphia, and Oroboros Instruments. The company was formerly known as NeuroVive Pharmaceutical AB (publ) and changed its name to Abliva AB (publ) in May 2020. Abliva AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden.
Abliva AB(Publ)開發治療原發線粒體疾病的藥物。該公司正在開發KL1333，它處於慢性治療初級線粒體疾病的2/3階段臨牀試驗；NV354，正在準備治療複雜I缺乏的初級線粒體疾病的臨牀試驗；以及NeuroSTAT，處於創傷性腦損傷的1b/2a階段臨牀研究。它與異構酶、永進製藥、賓夕法尼亞大學、費城兒童醫院和奧羅博羅斯儀器公司達成了合作協議。該公司前身為NeuroVive Pharmtics AB(Publ)，並於2020年5月更名為Abliva AB(Publ)。Abliva AB(Publ)成立於2000年，總部設在瑞典隆德。
About Cogent Biosciences
關於Cogent Bioscions
(Get Rating)
(獲取評級)
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Cogent Biosciences，Inc.是一家生物技術公司，專注於為基因定義的疾病開發精確療法。它的主要候選產品包括CGT9486，一種選擇性酪氨酸激酶抑制劑，旨在抑制導致系統性肥大細胞增多的KIT D816V突變，以及KIT外顯子17的其他突變，這些突變在晚期胃腸道間質瘤患者中發現。它與Plexxikon Inc.就貝祖拉替尼的研究、開發和商業化達成了一項許可協議。該公司前身為Unum治療公司，並於2020年10月更名為Cogent Biosciences，Inc.。Coent Biosciences，Inc.成立於2014年，總部位於馬薩諸塞州劍橋市。
Receive News & Ratings for Abliva AB (publ) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abliva AB (publ) and related companies with MarketBeat.com's FREE daily email newsletter.
接受Abliva AB(Publ)日報的新聞和評級-在下面輸入您的電子郵件地址，以通過MarketBeat.com的免費每日電子郵件時事通訊接收對Abliva AB(Publ)和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧